washington  reuters    mylan nl chief executive officer heather bresch will appear at a sept   congressional hearing over price increases for its epipen emergency allergy treatment  the u s  house of representatives oversight committee said in a statement on wednesday  mylan has been widely criticized  including by u s  democratic presidential candidate hillary clinton  for sharply raising the price of epipens  which are carried by people with life threatening allergies  mylan  which acquired the product in   recently raised the list price for a pair of epipen auto injectors to    the price has been rising from a cost of about   in    mylan spokeswoman nina devlin confirmed that bresch will attend the hearing   heather is very good at being able to give an answer without offering much information   said evercore isi analyst umer raffat  adding that he will be watching for any other issues that might be raised by the committee   a probe into epipen pricing by a u s  senate subcommittee was announced on sept    bresch is the daughter of u s  senator joe manchin  a democrat from west virginia  the house panel co chairmen  republican representative jason chaffetz and democratic representative elijah cummings  noted there is      justified outrage from families and schools across the country struggling to afford the high cost of epipens   the committee planned to look at how to spur competition in the epipen market and speed approval by the food and drug administration  fda  of generic alternatives  according to the statement  in response to the furor  mylan last month said it would sell its own generic version of epipen for    teva pharmaceutical industries  which for years has been working on developing a generic alternative to epipen  said last week that it hopes to gain u s  approval by late  or early   epipen  which has annual sales of about   billion  delivers a potentially life saving dose of epinephrine by injection into the thigh to counter dangerous allergic reactions  including to peanuts and bee stings  mylan owns  percent of the market for such auto injected devices  the committee said it also planned to call as a witness dr doug throckmorton  the fda s deputy director at the center for drug evaluation and research      